← Oncology Approval Tracker

FDA DECISION ·

Truqap + fulvestrant

capivasertib + fulvestrant · AstraZeneca

FDA approvalNew therapyBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer and a qualifying PIK3CA, AKT1, or PTEN alteration after progression on endocrine therapy for metastatic disease or recurrence during or within 12 months after adjuvant therapy.

LAMPGEN ANALYSIS

Why it matters

The approved regimen links AKT inhibition to a defined molecular subset following endocrine treatment.

What research teams should watch

Capture the assay, alteration, prior endocrine treatment, and timing of recurrence before making eligibility determinations.

PRIMARY RECORDS

Sources